Abstract

Red Resonance™ is a patent-pending photoreactive botanical oil designed to interact with endogenously generated red and near-infrared (NIR) light in human tissues to stimulate regenerative pathways. Unlike conventional photobiomodulation (PBM) devices, Red Resonance™ harnesses passive absorption of metabolic light via natural chromophores and lipid-soluble antioxidants derived from plants. This white paper details the scientific rationale, phytochemical composition, formulation methods, proposed mechanism of action, and preliminary safety and regulatory evaluations.

Introduction

Biophotonic emissions from human cells—particularly in the red/NIR spectrum—correlate with mitochondrial oxidative metabolism. Molecules such as cytochrome c oxidase and flavins emit and absorb photons between 600–950nm. By delivering exogenous, lipid-soluble compounds that can absorb this light and facilitate intracellular healing responses, the Red Resonance™ formulation represents a novel convergence of plant biochemistry and biophotonics.

Formulation Brief

Target: Systemic regenerative support through endogenous light interaction

Delivery forms: Oral (softgel), Topical (oil, serum), Transdermal (patch)

Mechanism of Action

This formulation interacts with internally emitted red/NIR light through:

• Photon Absorption: Internal red/NIR light (~650–900nm) is absorbed by hypericin, curcumin, and carotenoids.

• Cellular Activation: Absorbed light increases cytochrome c oxidase efficiency → increased ATP output.

• Redox Modulation: Curcumin and sesamin reduce ROS load and inflammatory cytokines (e.g., IL-6, TNF-α).

• Systemic Impact: Enhanced healing in muscle, skin, brain, and connective tissues

Understanding Internal Red/NIR Light

Human tissue, particularly mitochondria, emit small amounts of near-infrared (NIR) and red light during metabolic activity. This light is absorbed by internal chromophores like cytochrome c oxidase, modulating cellular functions such as ATP production, inflammation reduction, and gene expression (Avci et al.).

Certain plant-based compounds—especially carotenoids, polyphenols, and curcuminoids—can interact with these wavelengths, either by enhancing photonic absorption or by participating in energy transfer or antioxidant defense systems (Flieger et al., 2024).

Concept: Photoreactive Botanical Oil

A next-gen oil formulation can be designed to resonate with and amplify internal red/NIR energy, aiding in repair of vascular, muscular, neural, and epithelial systems.

PROBLEM
Chronic wounds, inflammatory skin conditions, and slow-healing injuries remain major public health burdens. Conventional therapies often rely on devices, invasive procedures, or steroids—limited by cost, accessibility, and side effects.

SOLUTION
BioPhotonic Oil is a first-in-class, plant-based topical formulation designed to work with red and near-infrared light already present inside the body to stimulate tissue regeneration, reduce inflammation, and accelerate healing—without requiring external light devices.

TECHNOLOGY

• Proprietary blend of GRAS botanical extracts (e.g., turmeric, frankincense, ginger) with documented anti-inflammatory and antioxidant effects

• Photoreactive carrier oils optimized for absorption at 660–850 nm

• Optional use of plant-derived extracellular vesicles for signal amplification

• No drug-device classification needed (topical biologic/cosmeceutical model)

Regulatory & Safety Dossiers

GRAS Status & Dietary Use Review

Conclusion: All ingredients are either GRAS or accepted in food/dietary applications under controlled dosing. St. John’s Wort requires pharmacovigilance labeling. Full ingredient list available upon request for clinicians, regulators, or qualified reviewers. Formula patent-pending.

MARKET OPPORTUNITY

• $10B+ market for wound healing, burns, and regenerative skin care

• Expanding consumer demand for light-based therapy and clean, plant-powered solutions

• Targeted applications: OTC cosmeceuticals, clinical dermatology, Rx for post-surgical use, global wellness markets

VALIDATION

• Patent-pending formulation (USPTO #63/XXXXXX)

• Preclinical lab designs (stability, photoreactivity, in vitro studies)

• IRB-ready Phase I pilot study protocol drafted

• NIH SBIR Phase I proposal drafted for $275K in federal seed funding